More like this
Gard Prefect Lets Perrier Keep Its Natural Mineral Water Boreholes
Nestlé Waters Supply Sud Source Perrier, Vergèze, Nîmes, Gard, Occitania, Metropolitan France, 30310, FranceNestlé
CONFIRMED88% CONFIDENCE280 days agoGard prefecture: 'L'arrêté préfectoral d'autorisation d'exploiter N°30 2025 12 18 00009 a été publié ce jour' (published 19/12/2025); Actualités News Environnement: 'un arrêté préfectoral du 18 décembre 2025 y autorise l'exploitation des forages Romaine VI et Romaine VII'.[1]The prefect authorised Nestlé Waters Supply Sud to bottle 'Source Perrier' natural mineral water at Vergèze from only the Romaine VI and VII boreholes, with three others disconnected and 24 months of reinforced health checks.0.70French Senate Inquiry Says State Covered Up Nestlé's Mineral Water Fraud
CONFIRMED86% CONFIDENCE1.3 years agoAP, datelined Paris 19 May 2025: 'a Senate inquiry commission said Monday'; Public Sénat: the senators 'ont rendu leurs conclusions ce lundi 19 mai'. The Senate's notice gives the filing: 'Rapport n° 628 (2024-2025), tome I, déposé le 14 mai 2025'.[1]After six months and 73 hearings, a Senate commission said the French state hid Nestlé Waters' use of banned treatments on Perrier, Vittel, Contrex and Hépar, a fraud France's fraud-control agency puts at over 3 billion euros.0.61Abbott and Google Partner on Lingo Glucose Insights and AI Coaching
CONFIRMED85% CONFIDENCE44 days agoThe release is datelined "ABBOTT PARK, Ill., Aug. 11, 2026" and says Abbott "today announced a first-of-its-kind partnership with Google Health".[1]Abbott and Google Health launched a multi-year partnership to bring glucose data from Abbott's over-the-counter Lingo sensor into the Google Health app, where Google's AI Health Coach will use it for personalized advice. The deal includes one of the largest real-world metabolic health studies.0.60FDA Authorizes Abbott's Libre Duo Glucose-Ketone Sensor
CONFIRMED87% CONFIDENCE30 days agoThe release is datelined "ABBOTT PARK, Ill., Aug. 25, 2026" and says Abbott "today announced U.S. Food and Drug Administration (FDA[2][3]) authorization of its Libre Duo 10 Day system"; the FDA's De Novo record gives the same decision date, 08/25/2026.The FDA authorized Abbott's Libre Duo 10 Day, the first wearable to continuously track both glucose and ketones, which alerts people with diabetes aged 2 and older to rising ketones before diabetic ketoacidosis.0.60WHO Ends the COVID-19 Public Health Emergency
CONFIRMED85% CONFIDENCE3.4 years agoThe WHO's[1] own statement on the fifteenth emergency committee meeting is dated 5 May 2023 and announces the end of the emergency.Three years and three months after declaring it, the WHO ended COVID-19's status as a public health emergency of international concern. The Director-General was careful to say the virus was not gone - only that it no longer needed emergency governance.0.59Construction Starts on the New Hillingdon Hospital
Hillingdon Hospital, Pield Heath Road, Uxbridge, London, EnglandThe Hillingdon Hospitals NHS Foundation Trust
ESTIMATED50% CONFIDENCEin 1.3 yearsThe council's update says Hillingdon[1] proceeds as a wave 1 scheme "with construction expected to start in 2027/28" and lists "Construction 2028 - 2032", a year rather than a date.The only London scheme in wave one of the New Hospital Programme puts a net-zero replacement hospital on the western edge of the Uxbridge site, with 327 homes alongside it, inside a capital envelope of GBP 1-1.5bn. Laing O'Rourke signed the delivery contract on 30 July 2026; the trust's milestones run construction to 2032 with the hospital available to patients in early 2033.0.59MenQuadfi's Phase 3 Trial in Meningococcal Infection Reads Out
ESTIMATED50% CONFIDENCEin 1.5 yearsClinicalTrials.gov[1] lists 2028-03-13 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.Sanofi's phase 3 trial of MenQuadfi in meningococcal infection reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,568 participants. The purpose of this study is to describe the safety and immunogenicity of MenACYW conjugate vaccine compared with locally-licensed meningococcal vaccines in healthy infants and toddlers in China. Study details include: * Study duration (including 6-month safety follow-up after the last dose): * Cohort I (Groups 1 and 2): approximately 211 or 271 days (approximately 7 or 9 months) * Cohort II (Groups 3 and 4): up to 18 months * Cohort III (Groups 5 and 6): up to 21 months * Cohort III (Group 7): approximately 16 months * Vaccination Visits Period: * Cohort I (Groups 1 and 2): a 2-dose vaccination at V01 (D01) and V02 (D31) or V03 (D91). Two blood samples are collected pre-vaccination (D01) and 30 days post the 2nd dose of vaccination (D61 or D121). Telephone calls (TCs) are planned on the 4th, the 9th, and the 21st day after each vaccination, and 5 TCs (1 TC/month) are planned for the 5 m0.59BGF MDI 320/14.4/9.6 μG's Phase 3 Trial in COPD Reads Out
ESTIMATED50% CONFIDENCEin 1.2 yearsClinicalTrials.gov[1] lists 2027-12-03 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.AstraZeneca's phase 3 trial of BGF MDI 320/14.4/9.6 μG in copd reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 5,000 participants. This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.0.59Second Gotthard Road Tunnel Due to Complete
SCHEDULED76% CONFIDENCEin 4.3 yearsA mid-2025 setback added cost and rework but the project team says it is still on schedule. Given as scheduled, per the source[1]: "It is due to be completed in 2030."Switzerland's second bore under the Gotthard Pass, approved by referendum in 2016 to let the original 1980 tunnel close for renovation without cutting off the A2, is on track to finish by 2030.$2.7B0.59Abbott's Amulet 360 LAA Occluder Wins CE Mark
CONFIRMED88% CONFIDENCE28 days agoThe release is datelined "ABBOTT PARK, Ill., Aug. 27, 2026" and says Abbott "announced today it has received CE Mark for the Amulet 360 Left Atrial Appendage (LAA) Occluder".[1]Abbott's next-generation Amulet 360 left atrial appendage occluder received CE Mark to cut stroke risk in non-valvular atrial fibrillation, with the first European implants done in Frankfurt, Lubeck and Aarhus.0.58Cagrisema's Phase 3 Trial in Obesity Reads Out
ESTIMATED50% CONFIDENCEin 1.4 yearsClinicalTrials.gov[1] lists 2028-02-23 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.Novo Nordisk's phase 3 trial of Cagrisema in obesity reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,500 participants. This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive either CagriSema or semaglutide, and which treatment participants receive is decided by chance. CagriSema is a new study medicine being tested, while semaglutide is a medicine that doctors can already prescribe. The study will last for about 83 weeks0.58GPT-5 Instant Update Better Supports People in Distress
CONFIRMED95% CONFIDENCE356 days agoOpenAI's[1] own model release notes date this entry October 3, 2025OpenAI updates GPT-5 Instant to better recognize and support people showing signs of mental and emotional distress.0.58
